A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

por Chang-Monteagudo, Arturo, Ochoa-Azze, Rolando, Climent-Ruiz, Yanet, Macías-Abraham, Consuelo, Rodríguez-Noda, Laura, Valenzuela-Silva, Carmen, Sánchez-Ramírez, Belinda, Perez-Nicado, Rocmira, Hernández-García, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, García-García, María de los Ángeles, Jerez-Barceló, Yanet, Triana-Marrero, Yenisey, Ruiz-Villegas, Laura, Rodríguez-Prieto, Luis Dairon, Puga-Gómez, Rinaldo, Guerra-Chaviano, Pedro Pablo, Zúñiga-Rosales, Yaíma, Marcheco-Teruel, Beatriz, Rodríguez-Acosta, Mireida, Noa-Romero, Enrique, Enríquez-Puertas, Juliet, Porto-González, Delia, Fernández-Medina, Olivia, Valdés-Zayas, Anet, Chen, Guang-Wu, Herrera-Martínez, Luís, Valdés-Balbín, Yury, García-Rivera, Dagmar, Verez-Bencomo, Vicente
Publicado 2021